Cargando…

Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)

[Image: see text] Introduction: Breast cancer is the most serious cause of women’s death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes’ hydrophilic core is essen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shakouri, Amir, Kahroba, Houman, Hamishekar, Hamed, Abdolalizadeh, Jalal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905592/
https://www.ncbi.nlm.nih.gov/pubmed/35411300
http://dx.doi.org/10.34172/bi.2021.39
_version_ 1784665220657971200
author Shakouri, Amir
Kahroba, Houman
Hamishekar, Hamed
Abdolalizadeh, Jalal
author_facet Shakouri, Amir
Kahroba, Houman
Hamishekar, Hamed
Abdolalizadeh, Jalal
author_sort Shakouri, Amir
collection PubMed
description [Image: see text] Introduction: Breast cancer is the most serious cause of women’s death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes’ hydrophilic core is essential to develop a therapeutic protein carrier system. We aimed to encapsulate the medicinal leech saliva extract (LSE) and assess the inhibition of angiogenesis of breast cancer cells by targeting vascular endothelial growth factor A (VEGFA). Methods: In this research, enhanced formulation of liposomal protein was determined by zeta potential analysis, droplet size, drug release assay, and transmission electron microscopy (TEM). Furthermore, a cytotoxicity assay of liposomal LSE was performed to determine the cytotoxic activity of components. For assessing the expression of VEGFA, P53, and hypoxia-inducible factor subunit alpha (HIF1a) genes, Real-Time PCR was applied. Results: Nano liposome was chosen as an enhanced formulation due to its much smaller size (46.23 nm). Liposomal LSE had more practical actions on the MCF-7 cells. As noticed by DAPI staining, apoptosis was extensively greater in treated MCF-7 cells. Wound healing assay demonstrated that MCF-7 cells could not sustain growth at the presence of liposomal LSE and expression of the VEGFA gene was declined in treated cells. Downregulation of VEGFA was evaluated with western blotting technique. Conclusion: It can be concluded that our investigation of the tests confirmed the fact that nano liposomal LSE is a novel promising formulation for anticancer drugs and can significantly improve the penetration of protein drugs to cancer cells.
format Online
Article
Text
id pubmed-8905592
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tabriz University of Medical Sciences (TUOMS Publishing Group)
record_format MEDLINE/PubMed
spelling pubmed-89055922022-04-10 Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7) Shakouri, Amir Kahroba, Houman Hamishekar, Hamed Abdolalizadeh, Jalal Bioimpacts Original Research [Image: see text] Introduction: Breast cancer is the most serious cause of women’s death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes’ hydrophilic core is essential to develop a therapeutic protein carrier system. We aimed to encapsulate the medicinal leech saliva extract (LSE) and assess the inhibition of angiogenesis of breast cancer cells by targeting vascular endothelial growth factor A (VEGFA). Methods: In this research, enhanced formulation of liposomal protein was determined by zeta potential analysis, droplet size, drug release assay, and transmission electron microscopy (TEM). Furthermore, a cytotoxicity assay of liposomal LSE was performed to determine the cytotoxic activity of components. For assessing the expression of VEGFA, P53, and hypoxia-inducible factor subunit alpha (HIF1a) genes, Real-Time PCR was applied. Results: Nano liposome was chosen as an enhanced formulation due to its much smaller size (46.23 nm). Liposomal LSE had more practical actions on the MCF-7 cells. As noticed by DAPI staining, apoptosis was extensively greater in treated MCF-7 cells. Wound healing assay demonstrated that MCF-7 cells could not sustain growth at the presence of liposomal LSE and expression of the VEGFA gene was declined in treated cells. Downregulation of VEGFA was evaluated with western blotting technique. Conclusion: It can be concluded that our investigation of the tests confirmed the fact that nano liposomal LSE is a novel promising formulation for anticancer drugs and can significantly improve the penetration of protein drugs to cancer cells. Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022 2021-08-09 /pmc/articles/PMC8905592/ /pubmed/35411300 http://dx.doi.org/10.34172/bi.2021.39 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc/4.0/ This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Research
Shakouri, Amir
Kahroba, Houman
Hamishekar, Hamed
Abdolalizadeh, Jalal
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
title Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
title_full Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
title_fullStr Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
title_full_unstemmed Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
title_short Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
title_sort nanoencapsulation of hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting vegfa in the breast cancer cell line (mcf-7)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905592/
https://www.ncbi.nlm.nih.gov/pubmed/35411300
http://dx.doi.org/10.34172/bi.2021.39
work_keys_str_mv AT shakouriamir nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7
AT kahrobahouman nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7
AT hamishekarhamed nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7
AT abdolalizadehjalal nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7